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ABSTRACT: Kappa opioid receptor (KOR) modulation has been
pursued in many conceptual frameworks for the treatment of human
pain, depression, and anxiety. As such, several imaging tools have
been developed to characterize the density of KORs in the human
brain and its occupancy by exogenous drug-like compounds. While
exploring the pharmacology of KOR tool compounds using positron
emission tomography (PET), we observed discrepancies in the appar-
ent competition binding as measured by changes in binding potential
(BPND, binding potential with respect to non-displaceable uptake).
This prompted us to systematically look at the relationships between
baseline BPND maps for three common KOR PET radioligands, the antagonists [
11C]LY2795050 and [11C]LY2459989, and the
agonist [11C]GR103545. We then measured changes in BPND using kappa antagonists (naloxone, naltrexone, LY2795050, JDTic,
nor-BNI), and found BPND was affected similarly between [
11C]GR103545 and [11C]LY2459989. Longitudinal PET studies with
nor-BNI and JDTic were also examined, and we observed a persistent decrease in [11C]GR103545 BPND up to 25 days after drug
administration for both nor-BNI and JDTic. Kappa agonists were also administered, and butorphan and GR89696 (racemic
GR103545) impacted binding to comparable levels between the two radiotracers. Of greatest significance, kappa agonists salvinorin
A and U-50488 caused dramatic reductions in [11C]GR103545 BPND but did not change [
11C]LY2459989 binding. This discrep-
ancy was further examined in dose−response studies with each radiotracer as well as in vitro binding experiments.
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■ INTRODUCTION
The opioid receptors (ORs) belong to the superfamily of
G-protein-coupled receptors (GPCRs) and consist of three
major subtypes: mu, kappa, and delta.1−4 While mu has been the
primary target of opioid analgesics, kappa opioid receptors
(KORs) are the most abundant ORs in the human brain and a
key regulator in a number of physiological systems, such as pain
regulation, motor function, stress response, andmood control.5,6
As a result, extensive efforts have been made to understand KOR
signaling,7−9 endogenous dynorphin-mediated receptor activa-
tion,10,11 and discovery and pharmacology of exogenous ligands
that bind to KORs. Early KOR drug discovery focused on
development of agonists that produced analgesic effects without
the liabilities associated with mu opioids, such as respiratory
depression and addiction.12 Unfortunately, it was discovered
that kappa agonists are aversive in humans, causing dysphoric,
depressive mood states and hallucinations.13,14 Recently, an
exciting new class of kappa agonists, termed G-protein-biased
agonists, have been developed.15−18 These drugs have demon-
strated analgesic efficacy in vitro and in vivo in animal pain
models, while largely avoiding dysphoric and other aversive
effects.19−21 Conversely, kappa antagonists have been developed
to treat negative mood states, and have progressed into phase I
clinical trials to potentially treat addiction, depression, and
anxiety.22−24 Together, kappa agonist and antagonist drug dis-
covery has been heavily pursued for a wide range of health
disorders from pain to neuropsychiatric illnesses. To support
this research, continued development and validation of tools to
study KOR pharmacology in vivo such as positron emission
tomography (PET) is essential.
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Several KOR agonist and antagonist pharmacophores have
been developed and investigated (Figure 1). The KOR
antagonists can be further divided into short- and long-acting
based on their effective duration of action. Naloxone and
naltrexone are short-acting KOR antagonists, but also have
affinity for mu and delta ORs. The aminobenzyloxyarylamides
are selective KOR antagonists originally reported by Lilly, later
entering clinical trials for major depressive disorder and sub-
stance abuse disorder (LY2456302, CERC-501).25,26 These
compounds were the first KOR-selective short-acting antago-
nists. Since this discovery, two compounds from the amino-
benzyloxyarylamide class have been radiolabeled with C-11 and
F-18, and are now clinically validated KOR PET radio-
tracers.27−29 JDTic and nor-BNI are long-acting KOR
antagonists that, while structurally unique to one another,
both have a delayed onset and long duration of action on KOR-
mediated effects.30,31 Nor-BNI was the first selective KOR
antagonist and has been used as a pharmacological tool in KOR
research, particularly in animal behavior studies to blunt KOR-
mediated effects.32−34 JDTic was evaluated in phase I clinical
trials as potential treatment for cocaine abuse, but the study was
terminated due to adverse events.22 One of the earliest KOR-
selective agonists was U-50488. This phenylacetamide is a
potent and selective KOR agonist with analgesic activity
in vivo.35 U-50488, and structural analog U-69593, have been
routinely used to interrogate KOR activation in both neuro-
biological and behavioral research.36−38 Derivation of this class
led to (±)GR89696 and GR103545 (active enantiomer, (−), of
GR89696),39 an ultra-potent kappa agonist that was later radio-
labeled with carbon-11 and studied with PET.40,41 Salvinorin A
is a natural product that belongs to the neoclerodane diterpene
chemical class. Its chemical scaffold is unique compared to most
KOR agonists (salvinorin A and collybolide analogs are the only
non-nitrogenous KOR agonists), but exhibits potent affinity and
extreme selectivity for KORs.42,43 Since its discovery, several
potent salvinorin derivatives have been discovered with unique
biochemical and pharmacological properties.16,19,44
Over the past 15 years, two classes of radiotracers for in vivo
imaging of KORs with PET have been developed, and both are
currently validated for human imaging. The KOR agonist
[11C]GR103545, was the first KOR PET radiotracer evaluated
clinically (Figure 1).45 Unfortunately, slow binding kinetics and
ultra-potency (requiring high specific activity to maintain
microdose levels) excluded this radiotracer from continued
use in humans, although preclinical studies have successfully
utilized this radiotracer.46 To circumvent this problem, a series
of KOR antagonist PET radiotracers were discovered and
evaluated in non-human primates and humans.27−29,47,48 Thus,
[11C]LY2795050 was the first clinically validated KOR antag-
onist radiotracer, although its moderate KOR selectivity and low
specific binding led to the development of [11C]LY2459989 and
[18F]LY2459989 (Figure 1).28,29 Previous PET studies on
KORs have focused on clinical validation of the aforementioned
radiotracers and in vivo drug-occupancy measurements of KOR
antagonists (e.g., PF-04455242, LY2456302).45,49 In either
clinical or preclinical PET studies, reports of drug occupancy
measurements with KOR agonists are lacking. As KOR agonist
medicinal chemistry continues to develop (largely around
G-protein-biased agonists),19,50,51 it will be important to have PET
radiotracers capable of measuring in vivo occupancy for both
KOR agonists and antagonists. Pharmacological PET experi-
ments with agonist drug challenge can prove difficult, especially
when studying dynamic protein targets such as GPCRs.52,53
In addition, a thorough evaluation and comparison of the two
classes of KOR radiotracers in rodents has not been reported.
Given the broad therapeutic application of KOR targeting drugs
and genetic and behavior rodent models used to study KORs, it
is important to understand which KOR radiotracers are best
suited for measuring drug occupancy of KOR ligands.
In this study, KOR PET studies in Sprague−Dawley rats were
conducted to determine differences, if any, of radioligand
sensitivity toward drug challenge with an array of KOR-specific
ligands (agonists and antagonists). This work was conducted to
compare three common KOR PET radioligands: the antagonists
[11C]LY2795050 and [11C]LY2459989, and the agonist
Figure 1. Kappa opioid receptor ligands and PET radiotracers used in this work.
[11C]GR103545 (Figure 1). Baseline PET scans with the agonist
radiotracer [11C]GR103545 were compared to the antagonist
radiotracer [11C]LY2459989 to assess any regional specific bind-
ing differences. Binding potential with respect to non-displaceable
binding (BPND) was calculated with PMOD using Logan Refer-
ence analysis. Blocking experiments with KOR antagonist drugs
(naltrexone, naloxone, LY2795050, JDTic, nor-BNI) were con-
ducted with PET to measure competitive binding dynamics for
each radiotracer. Lastly, several KOR agonists (butorphan,
U-50488, GR89696, and salvinorin A) were administered in
blocking experiments to measure each radioligand’s displacement
by agonist drug challenge. Lastly, GR103545 and LY2459989
in vitro binding was evaluated in wild-type and mutated KORs
(D138N).
■ RESULTS AND DISCUSSION
Radiochemistry. Previous synthesis of [11C]LY2795050
and [11C]LY2459989 was accomplished by heating the aryl
iodide precursor and Pd2(dba)3/dppf, with
11C-HCN for 5 min
followed by thermal hydrolysis (5 min with H2O2) using
conventional heating at 80 °C.28 In an effort to expedite this
process and improve specific activity, the aryl bromide precursor
was subjected to rapid microwave heating followed by hydrolysis
at ambient temperature. We observed rapid conversion of aryl
bromide to 11C-aryl-CN, and highest radiochemical yields were
obtained using 80 W of power for 20 s. At this power and time,
we observed nearly complete consumption of 11C-HCN to 11C-
aryl-CN. Immediately following microwave heating, H2O2 was
added and the reaction stirred for 2 min at ambient temperature.
With this process, we reduced the reaction time from 10 to
2.33 min while improving radiochemical yield (from 12 to 21%)
and improved specific activity (from 0.64 to 2.2−3.0 mCi/nmol
at EOS). Using this method, similar radiochemical yields were
obtained for both [11C]LY2795050 and [11C]LY2459989
(Figure 2). [11C]GR103545 was synthesized from the
normethylcarbamoyl precursor according to methods identical
to those previously reported.46
PET Imaging Comparison of [11C]GR103545 and
[11C]LY2459989 in Rats. Initial studies measuring rat KOR
binding with PET were performed with a first generation KOR
antagonist radiotracer, [11C]LY2795050. In rat brain, we observed
low specific binding and poor dynamic range in regions known
to have high KOR expression: nucleus accumbens (NACC),
amygdala (AG), caudate putamen (CPU), hypothalamus
(HTH), olfactory (OLF), midbrain (MB), thalamus (THA),
and periaqueductal gray (PAG).54−56 Given the relatively low
abundance of KOR density in the rat brain compared to both
human and non-human primates,55 we averaged several regions of
interest (ROIs), selected based on highest specific binding, and
designated as “high binding” (nucleus accumbens, amygdala,
caudate putamen, hypothalamus, midbrain, olfactory, thalamus,
periaqueductal gray, ventral tegmental area). This averaged ROI
has been used to examine [11C]LY2795050 (high binding BPND =
0.351 ± 0.047, n = 3)56,57 and all other KOR radiotracers
examined in this work. Fortunately, during our studies a second
generation KOR antagonist PET radiotracer was reported,
[11C]LY2459989.28 Since no prior rodent PET studies were
reported with [11C]LY2459989, we measured regional-specific
binding and compared to [11C]LY2795050. [11C]LY2459989
demonstrated higher specific binding in rat brain regions known
to have high KOR expression (high binding BPND 0.560± 0.046,
n = 5). In addition, [11C]LY2459989 was compared to KOR
agonist PET radiotracer [11C]GR103545 to determine differ-
ences, if any, of regional specific binding patterns in rats (Figure 3).
Both radiotracers exhibited highest specific binding (BPND) in
the hypothalamus followed by moderate uptake in the ventral
tegmental area, periaqueductal gray, nucleus accumbens, mid-
brain, and amygdala. Lowest uptake was observed in the cere-
bellum, and was used as a reference region to calculate BPND
(Logan Reference analysis). Our data indicate a strong correlation
of regional specific binding patterns between the antagonist
[11C]LY2459989 and the agonist [11C]GR103545 (Figure 3).
We also compared regional brain time-activity curves for each
radioligand at baseline and following naloxone pretreatment.
These data indicate favorable kinetics for all three ligands in rats,
despite the slow washout in humans previously reported for
[11C]GR103545 (see Supporting Information (SI) for time−
activity curves).
Blocking Studies with KOR Antagonists. We previously
reported in vivo KOR occupancy of salvinorin A and agonist-
induced receptor binding dynamics using [11C]GR103545 PET.46
This work was originally investigated with [11C]LY2795950, and
Figure 2. Improved synthesis of [11C]LY2795050 and [11C]LY2459989. Microwave heating resulted in high radiochemical yield, shorter total
synthesis time, and improved specific activity compared to conventional conditions.
again with [11C]LY2459989, but both ligands failed to demon-
strate a dose−occupancy relationship with salvinorin A. These
results prompted a thorough examination of the sensitivity of
KOR radiotracers toward pharmacological challenge with KOR
targeting ligands. Table 1 is a summary of all blocking studies
conducted with each radiotracer. Comparison of [11C]-
GR103545 and [11C]LY2459989 was first conducted by
pretreating animals with short-acting nonspecific and specific
KOR antagonists (naltrexone, naloxone, LY2795050) to measure
changes in [11C]LY2459989 or [11C]GR013545 BPND. Pretreat-
ment with naltrexone (2 mg/kg, i.v., 5 min pretreatment) followed
by KOR radiotracer bolus (i.v., ∼1 mCi), significantly reduced
high binding BPND of both [
11C]GR103545 (BPND < 1% of
baseline) and [11C]LY2459989 (BPND < 1% of baseline).
Pretreatment with naloxone (2 mg/kg, i.v., 5 min pretreatment)
resulted in a similar marked decrease in specific binding for
[11C]GR103545 (BPND = 20% of baseline) and [
11C]LY2459989
(BPND = 16% of baseline). In addition to naltrexone and naloxone,
which have affinity for all OR subtypes, we attempted blocking
experiments with the KOR-specific antagonist LY2795050.
LY2795050 (i.v., 5 min pretreatment) dose-dependently blocks
[11C]GR103545-specific binding at 0.032 mg/kg (BPND = 66%
of baseline) and 0.32 mg/kg (BPND = 17% of baseline). Specific
binding of [11C]LY2459989 is also significantly reduced when
animals are pretreated with 0.32 mg/kg of LY2795050 (BPND =
19% of baseline).
To further examine any possible discrepancies in KOR occu-
pancymeasurements, we administered KOR-specific antagonists
nor-BNI and JDTic to rats prior to radiotracer bolus (Table 1).
Nor-BNI and JDTic are unique KOR antagonists that produce
sustained antagonistic effects on KOR-mediated behavior58 and
signaling59 (e.g., behavioral effects by nor-BNI have been
reported to persist up to 86 days in rodents).60 Nor-BNI
is a bivalent ligand derived from naltrexone. JDTic is a
4-phenylpiperidine derivative that also displays high affinity
and selectivity for KORs. A pharmacokinetic (PK) study was
previously reported describing the long duration of action for
both nor-BNI and JDTic.61 Contrary to behavior and signaling
data, both drugs are rapidly absorbed and eliminated from
plasma and exhibit low brain uptake after i.p. administration
(nor-BNI tmax = 30 min, Cmax,brain = 443 ng mL
−1 ; JDTic tmax =
30 min, Cmax,brain = 71 ng mL
−1).61 To compare with these PK
experiments, we administered drugs at 10 mg/kg (i.p.), and
allowed a 30 min uptake period prior to radiotracer bolus. Nor-
BNI reduced [11C]GR013545 specific binding (high binding
BPND = 47 ± 15% of baseline; n = 2), and to a lesser extent,
[11C]LY2459989 specific binding (high binding BPND = 62% of
baseline). JDTic reduced [11C]GR103545 specific binding
(high binding BPND = 46 ± 1% of baseline; n = 2) but only
slightly reduced [11C]LY2459989 specific binding (high binding
BPND = 84% of baseline). It has been estimated from PK studies
that peak unbound brain levels at 30 min for JDTic and nor-BNI
are 4 nM and 26 nM. Asmentioned in that study, those unbound
brain concentrations are likely inaccurate, because both JDTic
and nor-BNI would produce maximal occupancy at that dose
(10 mg/kg) given their sub-nanomolar affinity for KOR.8
Consistent with their speculation, our data indicates consid-
erable occupancy for both nor-BNI and JDTic when measured
with [11C]GR103545, but we observed lower occupancy when
measured with [11C]LY2795050 (Table 1).
To gain a better understanding of the long duration of action
for both nor-BNI and JDTic in vivo, we measured longitudinal
effects of nor-BNI and JDTic on [11C]GR103545 binding in vivo
with PET. Following our initial PET studies with nor-BNI and
Figure 3. Baseline specific binding comparison of [11C]GR103545 and [11C]-LY2459989 in Sprague−Dawley rats. Regional specific binding
(BPND) was calculated using Logan Reference analysis using cerebellum as reference region. PET images represent average BPND at baseline and
were fused onto Rat-T2-MRI template. BPND = mean ± standard deviation. Red asterisk on structures indicates radiolabel position. Brain region
abbreviations, HTH = hypothalamus, VTA = ventral tegmental area, PAG = periaqueductal gray, NACC = nucleus accumbens, MB = midbrain,
AG = amygdala, OLF = olfactory tubercle, INS = insular cortex, THA = thalamus, CPU = caudate putamen, HC = hippocampus, CIN = cingulate
cortex, FRT = frontal cortex, MTR = motor cortex, CBL = cerebellum. High Binding = average of HTH, VTA, PAG, NACC, MB, AG, OLF, THA,
and CPU.
JDTic at 30 min pretreatment, animals were recurrently scanned
at four additional time points (3 h, 7 days, 17 days, then 25 days
following drug administration). Nor-BNI and JDTic caused a
persistent decrease in [11C]GR103545 BPND up to 25 days after
drug treatment (Table 1). This persistent decrease in BPND was
observed for both nor-BNI (high binding BPND = 16% of
baseline) and JDTic (high binding BPND = 38% of baseline)
25 days after drug administration (Table 1 and Figure 4).
These results were somewhat unexpected given that others have
shown with ex vivo experiments in mice, KOR receptor density
(Bmax) and agonist affinity (Kd) were conserved following
nor-BNI treatment.59 These ex vivo experiments were conduc-
ted with mouse brain membranes harvested 7 days after nor-BNI
treatment (10 mg/kg, i.p.), and incubated with [3H]U69,593,
so a direct comparison to our results is challenging. Additional
in vivo PET studies with nor-BNI- or JDTic-treated animals need
to be investigated to understand this phenomenon. Radiotracer
administration paradigms such as bolus/infusion,63 followed
by KOR agonist or antagonist drug challenge, could provide
additional evidence on receptor availability toward certain
KOR pharmacophores. Taken together with our in vivo data as
well as other reports on nor-BNI and JDTic mechanistic
studies,59,61,62 these drugs impose sustained effects on KOR-
mediated behavior, signaling, and radiotracer binding in vivo.
Blocking Studies with KOR Agonists.We had previously
investigated salvinorin A occupancy with PET and failed to
observe a dose−occupancy relationship with [11C]LY2795050
or [11C]LY2459989. While unexpected, this discrepancy has
been reported for other GPCRs such as dopamine receptor.64
Given the wide chemical (structural) and pharmacological
diversity of KOR targeting drugs that have been reported, and
the two classes of KOR PET radiotracers available (phenyl-
acetamide, KOR agonist; benzyloxyarylamide, KOR antagonist),
we measured KOR agonist drug occupancy with [11C]GR103545
and compared results to [11C]LY2795050 and [11C]LY2459989
(Table 1). Butorphan (MCL-101) is a full agonist at KORs,
derived from the morphinan class of opioids.65 Our results
with morphinan KOR antagonists (i.e., naloxone, naltrexone)
demonstrated complete blockade of radiotracer-specific binding,
as anticipated. Butorphan was chosen because of its structural
Table 1. Pharmacological PET Experiments Conducted with KOR Radiotracer in Ratsa
aBPND’s represent data from high binding ROIs. Further studies with [
11C]LY2795050 were replaced by the improved KOR antagonist radiotracer
[11C]LY2459989.28 Dashes indicate study not attempted. For replicates, mean ± standard deviation is reported. All other values are n = 1. All
compounds were administered i.v. except for JDTic and nor-BNI (i.p.). JDTic and norBNI treated animals were administered radiotracer bolus and
subseqent PET scan 30 min, 3 h, and 25 days following drug treatment.
similarity to naloxone and naltrexone, but has a different
pharmacological effect (full agonist at KORs). Butorphan was
administered to rats (0.1 mg/kg, i.v., 5 min pretreatment) prior
to [11C]LY2459989 bolus. In high KOR density regions in the
rat brain, [11C]LY2459989 BPND was reduced to 84% of baseline.
At higher dose, 1 mg/kg, [11C]LY2459989 BPND was significantly
reduced to 29%of baseline andwas comparable to [11C]GR103545
BPND (reduced to 34% of baseline from 1 mg/kg butorphan).
GR103545, (−)GR89696, is a potent full agonist at KORs
(Ki 20 pM, EC50 23 pM) and belongs to the phenylacetamide
class of KOR agonists.39 In our previous studies, we investigated
[11C]GR103545 BPND changes following LY2795050 admin-
istration (0.032 and 0.32 mg/kg, i.v., 5 min pretreatment). The
inverse paradigm was also examined by administering racemic
GR103545, (±)GR89696 (0.2 mg/kg, i.v.) followed by
[11C]LY2459989, which resulted in near complete block of
radioligand binding (BPND 21 ± 4%, n = 3). This indicates that
both GR103545 and LY295050/LY2459989 can block each
other’s specific binding (Table 1).
U-50488 is a potent full agonist at KORs (Kd = 1.8 nM)
66 and
a close structural analog of GR103545 (both drugs are
dichlorophenylacetamides). U-50488, like many KOR agonists,
produces analgesia in rodents and non-human primates, but in
humans is dysphoric and aversive.38,67 Previous studies measuring
U-50488 antinociception (paw pressure test) observed effects
from 1 to 10mg/kg (i.v.).67 In our experiments, we administered
(±)U-50488 (1 mg/kg, i.v.) 5 min prior to radiotracer bolus and
measured changes in specific binding. At 1 mg/kg, [11C]-
GR103545 BPND in high binding region is significantly reduced
to 19% of baseline. Surprisingly, the same pretreatment dose of
(±)U-50488 did not change [11C]LY2459989 BPND (BPND =
95 ± 17% of baseline, n = 2) (Table 1).
Salvinorin A is a unique KOR agonist with rapid onset and
short duration of action.68 A natural product derived from Salvia
divinorum, this neoclerodane diterpene has high KOR affinity
(Ki = 1.3 ± 0.5 nM)
69 and selectivity (>10 000:1) over mu
and delta opioid receptors.42 We previously reported the
quantification of salvinorin A levels in the rat brain with
[11C]GR103545 PET.46 This work was originally initiated with
[11C]LY2795050, but we failed to see a change in binding
potential relative to baseline scans. When salvinorin A is
administered at moderate doses (0.6 mg/kg, i.v., 1 min
pretreatment) or high doses (1.8 mg/kg, i.v., 1 min pretreat-
ment), [11C]GR103545 BPND is reduced to 63% and 26% of
baseline, respectively (Table 1). Interestingly, at 0.6 mg/kg,
[11C]LY2459989 BPND does not change from baseline levels,
and at 1.8 mg/kg only moderate changes in specific binding
were observed (BPND = 75% of baseline). Consistently,
[11C]LY2795050 BPND is only slightly reduced from 0.6 mg/kg
(BPND = 93% of baseline) (Table 1). Comparing dose−response
curves for [11C]GR103545, [11C]LY2459989, and [11C]-
LY2795050 following salvinorin A administration (Figure 5),
only [11C]GR103545 results in a sigmoidal fit allowing
estimation of ED50. [
11C]LY2795050 BPND was measured
following six escalating doses of salvinorin A (13, 16, 32, 100,
320, 600 μg/kg) all with little effect on specific binding.
[11C]LY2459989 BPND was measured following moderate to
high doses of salvinorin A (560, 600, 1000, 1800 μg/kg)
resulting in scattered effects with no apparent dose response
(Figure 5).
This discrepancy in [11C]LY2795050 and [11C]LY2459989
binding is difficult to rationalize without extensive interrogation,
but noncompetitive binding has been reported with other
GPCRs in vitro70,71 and in vivo.52 One aspect that is important to
discuss in these studies is the rate of dissociation for both drugs
and radiotracers and the impact of pharmacokinetics on
competitive binding. We have listed the pretreatment times
used for each drug to allow for interpretation of direct or indirect
competitive binding. While we fully understand that pretreat-
ment timing and rates of dissociation will affect radiotracer
binding, our pretreatment timing was consistent across both
classes of radiotracers to allow comparison. For drugs that have
rapid pharmacokinetics such as salvinorin A, a decrease in
radioligand binding in vivomay be the result of both competitive
Figure 4. Longitudinal effects of nor-BNI and JDTic on [11C]GR103545 binding measured in vivo with PET. Sprague−Dawley rats were treated with
JDTic or nor-BNI (10 mg/kg, i.p.) prior to radiotracer bolus. Following initial PET studies with nor-BNI and JDTic at 30 min pretreatment, animals
were recurrently scanned at four additional time points (3 h, 7 days, 17 days, then 25 days following drug administration). Both nor-BNI and JDTic
caused a persistent decrease in [11C]GR103545 BPND up to 25 days after drug administration. BPND listed represents average of high binding regions.
Due to technical issues, nor-BNI-treated animals were not scanned on day 17.
binding and receptor unavailability (i.e., receptor desensitization
or internalization). In a previous report, we measured long-term
effects of salvinorin A on [11C]GR103545 binding with PET by
scanning minutes to hours after drug treatment.46 In rat,
salvinorin A (i.v.) displays rapid uptake (tmax = 13 s) and fast
washout (t1/2 = 3.3 min), but we observed a persistent decrease
in [11C]GR103545 BPND at 2.5 h pretreatment time, long after
the drug had cleared from the brain. This indicates that at least
[11C]GR103545 is capable of measuring KOR availability
following agonist drug clearance.
In addition, KOR structural biology has not fully elucidated
receptor−ligand confirmations with all KOR pharmacophores.
To date there are two KOR crystal structures: one solved with
the antagonist JDTic,72 the other with the agonist MP-1104 and
an active-state stabilizing nanobody.9 A comparison of the
JDTic-bound conformation with the agonist state showed
considerable differences in the overall shape of the binding
pocket and conformations of key residues involved in binding
and signaling.9 As the discrepancies in our studies were only
observed with agonist drugs and antagonist radiotracers, it is
important to remember that these two types of drugs stabilize
distinct conformational ensembles.
Early attempts to understand KOR structure dynamics with
agonists was performed with NMR experiments. The
endogenous KOR ligand, dynorphin, bound to human KOR
revealed there are multiple bound states of the peptide that
result in a number of receptor conformations.11 A single model
of dynorphin-KOR binding was not determined due to the
observation of multiple conformers, all with similar energy.
Instead, a few “poses” were described the first being KOR-1,
defined as a representation of an inactive state of the receptor,
which can still bind to the KOR antagonist JDTic. The con-
formation of KOR-2 correlates with an activated state and binds
dynorphin with higher affinity. In a separate report, in silico
docking studies on KOR binding with four structurally diverse
agonists revealed multiple receptor conformations and binding
modes.73 Also, the mutation of certain residues in the active site,
altered binding of dynorphin A but not salvinorin A and
U-69593. Further, docking studies with U-69593, U-50488, and
salvinorin A indicated that these ligands bind to KORs in a
unique way, leading to a unique KOR structure in the bound
state. It is also conceivable that certain KOR PET radiotracers
are only capable of binding to certain KOR conformations.
As already mentioned, we recently solved the KOR structure
in its active state with the KOR agonist MP1104 (epoxy
morphinan).74 Although several conformational differences
were observed between the JDTic-KOR and MP1104-KOR
structure, a key ligand−receptor contact was identified that had
distinctive effects upon ligand binding when mutated, D138.
When D138 in transmembrane helix 3 is mutated, dynorphin
activity is abolished where as salvinorin A still maintains high
affinity at KOR, likely due its lack of a basic nitrogen which is
required for ligand−D138 interaction in agreement with prior
studies.75
In an effort to understand the binding differences between
GR103545 and LY2459989, in vitro radioligand binding assays
were carried out using KOR wild-type and a D138N mutant
(Figure 6). In KORWT, LY2459989Ki was 0.54± 0.04 nM and
GR103545 was 0.07 nM. In KORD138Nmutant, the binding of
LY2459989 was dramatically compromised (Ki = 287 nM ± 11;
Figure 5. Salvinorin A dose−response PET experiments conducted in vivo with three different KOR radiotracers. Only [11C]GR103545 showed
decreased specific binding in a dose-dependent manner. BPND’s represent data from high-binding ROIs. In all cases, salvinorin A was administered
intravenously 1 min prior to radiotracer.
Figure 6. In vitro radioligand binding studies in KOR wild-type and KOR mutant D138N with LY2459989, GR89696 (racemic GR103545),
GR103545, and diprenorphine. When KOR is mutated at D138 in the active site, affinity was essentially lost for LY2459989 but not GR89696 or
GR103545.
500-fold change); however, GR103545 still maintains high
affinity (2.9± 0.2 nM) which indicates that D1383.32 may not be
necessary for its binding. (Figure 6). In addition, we measured
affinity with conditions close to physiological environment
(HEPES buffer +100 mM NaCl) but our results show a similar
trend (SI, Figure S4). These data indicate LY2459989, and likely
other aminobenzyloxyarylamides, recognizes and bind a
receptor confirmation that is unique compared to other KOR
pharmacophores.
Pharmacological PET imaging is an important tool for
understanding drug-target engagement in the living brain.
Over the past decade, PET imaging of KOR has been successful
in validating two series of PET radiotracers. [11C]GR103545
and [11C]/[18F]LY2459989 have been evaluated in several
species including humans, and used to measure occupancy of a
few KOR antagonists in vivo with PET. Given that a large
number of KOR pharmacophores exist, and the increasing
interest in KOR therapeutics, it is important to understand any
binding discrepancies for these two radiotracers with an array of
KOR ligands. In rodents there is a tremendous opportunity to
study KOR function with PET, in particular, using genetic or
behavior models to help answer key neurobiological questions
about the role of dynorphin and KORs in health disorders. This
work highlights discrepancies we discovered during pharmaco-
logical PET studies in rats with [11C]GR103545, [11C]-
LY2459989, and [11C]LY2795050. Given the active develop-
ment of novel KOR ligand chemotypes and the potential of
KOR therapeutics, we envision an increased need for KOR PET
especially for measuring drug−target engagement in the human
brain. A thorough evaluation of the tools available for KOR PET
is important, as it is essential for understanding the consid-
erations and discrepancies that may exist when measuring KOR
drug occupancy in the living brain. Lastly, given the challenges
with [11C]GR103545 human PET imaging (i.e., strict mass limit
to avoid physiological effects, long scan times due to slow
radiotracer kinetics),45 the development of improved KOR
agonist PET radiotracers is needed.
■ MATERIALS AND METHODS
Materials. LY2795050 and radiolabeling precursor (corresponding
aryl bromide) were synthesized according to methods previously
reported.25,76 LY2459989 was synthesized according to methods
previously reported.28 The synthesis of LY2459989 precursor
(corresponding aryl bromide) is described in the SI. GR103545 stan-
dard and radiolabeling precursor (normethylcarbamoyl-GR103545)
were purchased from ABX Chemical. JDTic (JDTic dihydrochloride)
was supplied by F. Ivy Carroll and RTI International. Naloxone
(naloxone hydrochloride dihydrate), U-50488 ((±)-trans-U-50488
methanesulfonate), naltrexone (naltrexone hydrochloride), nor-BNI
(nor-binaltorphimine dihydrochloride), and butorphan (butorphan
S-(+)-mandelate) were purchased from Sigma-Aldrich (St. Louis, MO).
Reagents and solvents were purchased from Sigma-Aldrich
(St. Louis, MO) and used without further treatment unless specified.
Tetrakis(triphenylphosphine)palladium(0) was purchased from Strem
Chemicals (Newburyport, MA). For palladium-catalyzed cyanation,
anhydrous dimethyl sulfoxide was purchased form Sigma-Aldrich
(St. Louis, MO) and sparged with nitrogen prior to use.
Radiochemistry. Radioactivity was produced by an Eclipse HP 11
MeV cyclotron (Siemens Healthcare, Munich, Germany) using a 11C
gas target (N2 gas containing 2.5% O2) irradiated at 52 μA to produce
11C-CO2. HPLC purification of radiotracers was performed with an
Agilent 1200 series HPLC equipped with a diode array detector, Carroll
& Ramsey radiation detector (Model 105S), quaternary pump, and a
Vici injector port equipped with a 2 mL sample loop. Microwave
chemistry was performed with a Resonance Instruments Inc.
microwave reactor, Model 521 (Skokie, IL, USA). Purified, formulated
radiotracers were analyzed by analytical HPLC to measure radio-
chemical purity (≥98%), specific activity, and identity was confirmed by
co-injection with the appropriate 12C-standard. EOS = end of synthesis
(final formulation); NDC = nondecay-corrected; EOB = end of beam.
[11C]LY2459989 Radiosynthesis. 11C-CO2 was delivered to a
Siemens Healthcare Explora CN synthesis module with helium as a
carrier. 11C-CO2 was converted to
11C-CH4 with H2 on nickel at
400 °C, and then to 11C-HCN with NH3 on platinum at 900 °C.
11C-
HCN was bubbled at 12 psi directly into the 5 mL v-vial containing the
precursor (S)-3-(1-(4-(4-bromo-2-fluorophenoxy)benzyl)pyrrolidin-
2-yl)pyridine) (1.0 mg), Pd(PPh3)4 (1.2 mg), and K2CO3 (1.0 mg),
in DMSO (0.5 mL) at room temperature. When radioactivity peaked,
the reaction vial was subjected to microwave heating with stirring
(80 W, 25 s). The reaction was allowed to cool for 1 min before H2O2
(10%, 150 μL) was added, and the mixture was allowed to stir at room
temperature for 2 min. The mixture was diluted with mobile phase
(1.3 mL) and purified by semipreparative HPLC (9.4 × 250 mm
Agilent Eclipse XDB-C18, 5 μm) with ACN:H2O:TFA (17%: 82.9%:
0.1%) at 5mL/min. The product eluted at approximately 9min and was
diluted with water (20 mL), passed through a Sep Pak (C-18 plus,
conditioned with 1 mL ethanol followed by 10 mL water). The Sep Pak
was washed with sterile water (5 mL), and the final product was reverse
eluted with ethanol (1 mL) and diluted with saline (9 mL). The formu-
lated product was passed through a sterile filter (0.45 μm) into a sterile
vial ready for injection. [11C]LY2459989 was synthesized with an average
RCY of 29 ± 10% (EOS, NDC), average synthesis time of 30 min from
EOB, and an average specific activity of 2.7 ± 1.4 mCi/nmol at EOS.
[11C]LY2795050 Radiosynthesis. [11C]LY2795050 radiosynthesis
was conducted with conditions identical to [11C]LY2459989.
Purification of the crude reaction was performed on semipreparative
HPLC (9.4 × 250 mm Agilent Eclipse XDB-C18, 5 μm) with
ACN:H2O:TFA (20%: 79.9%: 0.1%) at 5 mL/min. The product eluted
at approximately 7 min and was diluted with water (20 mL), passed
through a Sep Pak (C-18 plus, conditioned with 1 mL ethanol followed
by 20 mL water). The Sep Pak was washed with sterile water (5 mL),
and the final product was reverse eluted with ethanol (1 mL) and
diluted with saline (9mL). The formulated product was passed through
a sterile filter (0.45 μm) into a sterile vial ready for injection.
[11C]LY2795050 was synthesized with an average RCY of 21 ± 8%
(EOS, NDC), average synthesis time of 30 min from EOB, and an
average specific activity of 2.5 ± 0.9 mCi/nmol at EOS.
[11C]GR103545 was synthesized and purified according to
methods identical to those previously published, with an average
RCY of 15.2 ± 6.1% (EOS, NDC) and an average specific activity of
6.9 ± 2.2 mCi/nmol at EOS.
Rodent PET and Image Analysis. Male Sprague−Dawley rats
were anesthetized with isoflurane (3% isoflurane for induction, 1.5% for
maintenance) with oxygen as a carrier. Rats were catheterized in a
lateral tail vein, connected to an extension line primed with heparinized
saline (0.9%), and placed in a head-first prone position on scanner bed.
For blocking experiments, animals received either a bolus i.v. injection
of drug or vehicle prior to administration of the radiotracer. All
compounds were administered intravenously except for JDTic and nor-
BNI (intraperitoneal). Compounds were formulated for injection as
follows: Salvinorin A (3:3:14 DMSO:Tween80:saline), LY2795050
(1:1:8 DMSO:Tween80:saline), U-50488 (saline), GR89696 (saline),
naloxone (saline), naltrexone (saline), butorphan (saline), nor-BNI
(saline), JDTic (saline). All formulations were diluted appropriately
to administer 2 mL/kg. [11C]GR103545, [11C]LY2795050, and
[11C]LY2459989 were formulated in 10% ethanol/90% saline and
administered intravenously (bolus, 0.7 ± 0.2 mCi) following vehicle or
drug challenge. Rodents underwent a 60 min dynamic PET scan
followed by a CT scan for attenuation and co-registration. Images were
reconstructed using an iterative MLEM (maximum likelihood expect-
ationmaximization) algorithm, and the data were binned into 32 frames
(8 × 15 s, 8 × 1 min, 10 × 2 min, 6 × 5 min). Raw images were
processed using PMOD 3.3 (PMOD Technologies, Zurich, Switzer-
land). Co-registered PET/CT images were spatially aligned to the
Schiffer rat brain template (Px Rat),77 and regional time−activity curves
were generated. Specific binding with respect to displaceable uptake
(BPND) was calculated using the Logan reference analysis method with
cerebellum as reference region, [11C]GR103545 t* = 20 min,
[11C]LY2459989 t* = 30 min, [11C]LY2795050 t* = 30 min.78−80
Nor-BNI and JDTic Longitudinal PET Study. Following initial
[11C]GR103545 PET studies with nor-BNI and JDTic (30 min
pretreatment), animals were recurrently scanned at four additional time
points (3 h, 7 days, 17 days, then 25 days following drug administra-
tion). After completion of the first scan (30 min time point), animals
were removed from isoflurane and returned to holding cages.
At approximately 2.5 h, animals were anesthetized again with isoflurane
(3% for induction, 1.5% for maintenance) and injected with
[11C]GR103545 bolus at 3 h from initial drug administration. Upon
completion of this second scan (3 h time point), animals were returned
to holding cages until next [11C]GR103545 PET scan on day 7, day 17,
or day 25. Due to technical issues, nor-BNI-treated animals were not
scanned on day 17. Scan parameters, data reconstruction, and analysis
methods were identical to those described above.
Radioligand Binding Assays. Binding assays were performed
using HEK293 T membrane preparations transiently expressing KOR
wild type or D138Nmutant. Binding assays were set up in 96-well plates
in the standard binding buffer (50 mM Tris, 0.1 mM EDTA, 10 mM
MgCl2, 0.1% BSA, pH 7.4) or HEPES buffer (25 mMHEPES, 100 mM
NaCl, pH 7.4) (SI, Figure S4). For the competition binding, 50 μL each
of 3H-diprenorphine (final 0.81 nM), drug solution (3×), and
homogeneous membrane solution was incubated in 96-well plate in
the standard binding buffer. Reactions were incubated for 2 h at room
temperature in the dark, terminated by rapid vacuum filtration onto
chilled 0.3% PEI-soaked GF/A filters followed by three quick washes
with cold washing buffer (50 mMTris HCl, pH 7.40), and read. Results
(with or without normalization) were analyzed using GraphPad Prism
5.0 using “one site-fit Ki” model.
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(8) Beǵuin, C., and Cohen, B. M. (2009) Medicinal Chemistry of
Kappa Opioid Receptor Antagonists BT - Opiate Receptors and
Antagonists, Opiate Receptors and Antagonists, pp 99−118, Humana
Press, Totowa, NJ.
(9) Che, T., Majumdar, S., Zaidi, S. A., Ondachi, P., McCorvy, J. D.,
Wang, S., Mosier, P. D., Uprety, R., Vardy, E., Krumm, B. E., Han, G.
W., Lee, M. Y., Pardon, E., Steyaert, J., Huang, X. P., Strachan, R. T.,
Tribo, A. R., Pasternak, G. W., Carroll, F. I., Stevens, R. C., Cherezov,
V., Katritch, V., Wacker, D., and Roth, B. L. (2018) Structure of the
Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell
172, 55−67.e15.
(10) Chavkin, C., James, I. F., andGoldstein, A. (1982)Dynorphin is a
specific endogenous ligand of the kappa opioid receptor. Science 215,
413−5.
(11) O’Connor, C., White, K. L., Doncescu, N., Didenko, T., Roth, B.
L., Czaplicki, G., Stevens, R. C., Wüthrich, K., and Milon, A. (2015)
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Zhao, Z., Carlezon, W. A., and Cohen, B. M. (2012) Long-acting e ̂
opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in
mice and lipophilicity. BMC Pharmacol. 12, 5.
(62)Owens, S.M., Pollard, G. T., Howard, J. L., Fennell, T. R., Snyder,
R. W., and Carroll, F. I. (2016) Pharmacodynamic Relationships
between Duration of Action of JDTic-like Kappa-Opioid Receptor
Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.ACS
Chem. Neurosci. 7, 1737−1745.
(63) Placzek,M. S., Zhao,W.,Wey, H. Y.,Morin, T.M., andHooker, J.
M. (2016) PET Neurochemical Imaging Modes. Semin. Nucl. Med. 46,
20−27.
(64) Guo, N., Guo, W., Kralikova, M., Jiang, M., Schieren, I.,
Narendran, R., Slifstein, M., Abi-Dargham, A., Laruelle, M., Javitch, J.
A., and Rayport, S. (2010) Impact of D2 Receptor Internalization on
Binding Affinity of Neuroimaging Radiotracers. Neuropsychopharma-
cology 35, 806−817.
(65) Neumeyer, J. L., Zhang, B., Zhang, T., Sromek, A. W., Knapp, B.
I., Cohen, D. J., and Bidlack, J. M. (2012) Synthesis, binding affinity,
and functional in vitro activity of 3-benzylaminomorphinan and 3-
benzylaminomorphine ligands at opioid receptors. J. Med. Chem. 55,
3878−3890.
(66) Rothman, R. B., France, C. P., Bykov, V., De Costa, B. R.,
Jacobson, A. E., Woods, J. H., and Rice, K. C. (1989) Pharmacological
activities of optically pure enantiomers of the κ opioid agonist, U50,488,
and its cis diastereomer: evidence for three κ receptor subtypes. Eur. J.
Pharmacol. 167, 345−353.
(67) Leighton, G. E., Rodriguez, R. E., Hill, R. G., and Hughes, J.
(1988) κ-Opioid agonists produce antinociception after i.v. and i.c.v.
but not intrathecal administration in the rat. Br. J. Pharmacol. 93, 553−
560.
(68) Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E.,
and Griffiths, R. R. (2011) Human psychopharmacology and dose-
effects of salvinorin A, a kappa opioid agonist hallucinogen present in
the plant Salvia divinorum. Drug Alcohol Depend. 115, 150−155.
(69) Wang, Y., Chen, Y., Xu, W., Lee, D. Y., Ma, Z., Rawls, S. M.,
Cowan, A., and Liu-Chen, L. Y. (2008) 2-Methoxymethyl-salvinorin B
is a potent kappa opioid receptor agonist with longer lasting action in
vivo than salvinorin A. J. Pharmacol. Exp. Ther. 324, 1073−1083.
(70) van Giezen, J. J. J., Nilsson, L., Berntsson, P., Wissing, B. M.,
Giordanetto, F., Tomlinson, W., and Greasley, P. J. (2009) Ticagrelor
binds to human P2Y12independently from ADP but antagonizes ADP-
induced receptor signaling and platelet aggregation. J. Thromb.
Haemostasis 7, 1556−1565.
(71) Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M.,
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